MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
52.30
+1.04
+2.03%
Opening 11:48 03/17 EDT
OPEN
51.02
PREV CLOSE
51.26
HIGH
53.00
LOW
50.07
VOLUME
270.90K
TURNOVER
--
52 WEEK HIGH
53.65
52 WEEK LOW
6.71
MARKET CAP
2.52B
P/E (TTM)
-19.4895
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 1d ago
Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $58
Benzinga · 1d ago
Wedbush Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)
TipRanks · 1d ago
Maze Therapeutics price target raised to $58 from $43 at Wedbush
TipRanks · 1d ago
Weekly Report: what happened at MAZE last week (0309-0313)?
Weekly Report · 1d ago
Maze Therapeutics President, R&D and CMO Harold Bernstein Disposes of Common Shares
Reuters · 4d ago
Qualcomm downgraded, Rivian upgraded: Wall Street’s top analyst calls
TipRanks · 03/10 13:35
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 03/10 12:50
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.